Spero Therapeutics stockholders approve 2M share increase to 2017 Stock Incentive Plan

Spero Therapeutics, Inc.

Stockholders approved amendment to 2017 Stock Incentive Plan, increasing authorized shares by 2,000,000 (total 4,608,374 for new awards).
Vote: 11,537,809 for, 8,787,318 against, 3,114,531 abstentions, 4,552,916 broker non-votes.
Directors Patrick Vink and Frank Thomas re-elected at annual meeting on September 15, 2022.
PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.